Announcements
- Celyad Oncology announces the termination of its American Depository Receipt program
- Publication of a rectified transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
- Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
- Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
- Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
- Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
- Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.249 |
---|---|
High | 0.249 |
Low | 0.249 |
Bid | 0.143 |
Offer | 0.4715 |
Previous close | 0.2655 |
Average volume | 0.00 |
---|---|
Shares outstanding | 41.43m |
Free float | 38.27m |
P/E (TTM) | -- |
Market cap | 12.99m EUR |
EPS (TTM) | -0.3287 EUR |
Data delayed at least 15 minutes, as of May 17 2024 07:05 BST.
More ▼